clinical trial · NCT03454451
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Non-Small Cell Lung CancerRenal Cell CancerColorectal CancerTriple Negative Breast CancerCervical CancerOvarian CancerPancreatic CancerEndometrial CancerCPI-006CPI-006 + ciforadenantCPI-006 + pembrolizumabCPI-006CPI-006 + ciforadenantCPI-006 + pembrolizumab
brief summary
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
started
Apr 25, 2018
primary completion
Dec 28, 2022
completion
Feb 19, 2023
last updated
Dec 21, 2023
official title
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol